30 April 2007
THE FINANCIAL EXPRESS (INDIA)—As the drug market moves to injectables, biotech majors strive to develop targeted-injection drugs for the treatment of a host of disorders. Indian biotech majors, however, seem steady on their path. Dabur Pharma, for instance, achieved a breakthrough with its Nanoxel, a drug delivery system for the widely used anti-cancer drug Paclitaxel. This nanoscale drug delivery system is India's first indigenously developed nanotechnology-based chemotherapy agent, and also the first outside of the US. Positioned as a safer therapy for advanced breast, non-small-cell lung, and ovarian cancers, it enables therapy to take a preferential course to the cancerous cells and directly interact with the tumor-causing agents thereby throwing open a larger window for anti-tumor activity. It also ensures that the patient receives the full measure of therapy while limiting the adverse side effects and toxicity affected by the drug. This would be a great advantage because the biggest challenge faced in cancer therapy is the incidence of severe side effects that the cancer patient has to encounter while undergoing chemotherapy. Source:
http://www.financialexpress.com/fe_full_story.php?content_id=162659 (Reliability: 7)
No comments:
Post a Comment